Remission & chronicity
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
ADIPOQ
DPP4
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TCDD | ? unclear | Mechanistic | DGIdb | |
| LINAGLIPTIN | ↓ inhibits | Mechanistic | DGIdb | |
| GOSOGLIPTIN | ↓ inhibits | Mechanistic | DGIdb | |
| BEGELOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| VALACYCLOVIR | ? unclear | Mechanistic | DGIdb | |
| GEMIGLIPTIN | ↓ inhibits | Mechanistic | DGIdb | |
| ENMD-2076 | ↓ inhibits | Mechanistic | DGIdb | |
| SITRAVATINIB | ↓ inhibits | Mechanistic | DGIdb | |
| CRENOLANIB | ↓ inhibits | Mechanistic | DGIdb | |
| CP-673451 | ↓ inhibits | Mechanistic | DGIdb | |
| NINTEDANIB ESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| IBCASERTIB | ↓ inhibits | Mechanistic | DGIdb | |
| LUCITANIB | ↓ inhibits | Mechanistic | DGIdb | |
| SAXAGLIPTIN ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| DBPR-108 | ↓ inhibits | Mechanistic | DGIdb | |
| M4205 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 8H [PMID: 22765894] | ↓ inhibits | Mechanistic | DGIdb | |
| DOVITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| MELOGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| PP-121 | ↓ inhibits | Mechanistic | DGIdb | |
| EVOGLIPTIN | ↓ inhibits | Mechanistic | DGIdb | |
| ILORASERTIB | ↓ inhibits | Mechanistic | DGIdb | |
| AC710 | ↓ inhibits | Mechanistic | DGIdb | |
| MASITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| ALOGLIPTIN BENZOATE | ↓ inhibits | Mechanistic | DGIdb | |
| QUIZARTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| CHMFL-KIT-64 | ↓ inhibits | Mechanistic | DGIdb | |
| VILDAGLIPTIN | ↓ inhibits | Mechanistic | 34.0 nM (IC50) | DGIdb |
| SERALUTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| CAPTOPRIL | ? unclear | Mechanistic | DGIdb | |
| TRELAGLIPTIN SUCCINATE | ↓ inhibits | Mechanistic | DGIdb | |
| ENALAPRIL MALEATE | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 8H [PMID: 21561767] | ↓ inhibits | Mechanistic | DGIdb | |
| TENELIGLIPTIN | ↓ inhibits | Mechanistic | DGIdb | |
| ELENESTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| CARMEGLIPTIN | ↓ inhibits | Mechanistic | DGIdb | |
| ANAGLIPTIN | ↓ inhibits | Mechanistic | DGIdb | |
| SITAGLIPTIN | ↓ inhibits | Mechanistic | DGIdb | |
| DUTOGLIPTIN | ↓ inhibits | Mechanistic | DGIdb | |
| BISEGLIPTIN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 234 agents ranked by evidence tier.
FOXO1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FAS LIGAND | ? unclear | Mechanistic | DGIdb | |
| FLUOROURACIL | ? unclear | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| EPIRUBICIN | ? unclear | Mechanistic | DGIdb | |
| PSAMMAPLYSENE A | ↓ inhibits | Mechanistic | 5000.0 nM (IC50) | ChEMBL |
| PSAMMAPLYSENE B | ↓ inhibits | Mechanistic | 20000.0 nM (IC50) | ChEMBL |
| CHEMBL5192734 | ↓ inhibits | Mechanistic | 33.0 nM (IC50) | ChEMBL |
| CHEMBL5410786 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5427016 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5430492 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5438402 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5422565 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5401913 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5416762 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5432660 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5440152 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5435132 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5435547 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5433566 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5424486 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5423837 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5410704 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5405275 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5440878 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL5413713 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| PANOBINOSTAT | ↑ activates | Mechanistic | 420.0 nM (EC50) | ChEMBL |
GCGR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| REDIOCIDE A | ? unclear | Mechanistic | DGIdb | |
| ADOMEGLIVANT | ↓ inhibits | Mechanistic | DGIdb | |
| GLUCAGON (RDNA) | ↑ activates | Mechanistic | DGIdb | |
| CROTEDUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEMETREXED DISODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| LGD-6972 | ? unclear | Mechanistic | DGIdb | |
| COTADUTIDE | ↑ activates | Mechanistic | DGIdb | |
| GLUCAGON HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| MK-0893 | ↓ inhibits | Mechanistic | DGIdb | |
| PEGAPAMODUTIDE | ? unclear | Mechanistic | DGIdb | |
| PF-06291874 | ↓ inhibits | Mechanistic | DGIdb | |
| EFINOPEGDUTIDE | ↑ activates | Mechanistic | DGIdb | |
| CAPECITABINE | ↓ inhibits | Mechanistic | DGIdb | |
| RALTITREXED | ↓ inhibits | Mechanistic | DGIdb | |
| DASIGLUCAGON HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| DASIGLUCAGON | ↑ activates | Mechanistic | DGIdb | |
| MK-3577 | ↓ inhibits | Mechanistic | DGIdb | |
| VOLAGIDEMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SAR425899 | ↑ activates | Mechanistic | DGIdb | |
| GLUCAGON | ? unclear | Mechanistic | Open Targets | |
| CHEMBL140267 | ↓ inhibits | Mechanistic | 7500.0 nM (IC50) | ChEMBL |
| CHEMBL346451 | ↓ inhibits | Mechanistic | 20000.0 nM (Ki) | ChEMBL |
| CHEMBL358250 | ↓ inhibits | Mechanistic | 120.0 nM (IC50) | ChEMBL |
| CHEMBL140209 | ↓ inhibits | Mechanistic | 6000.0 nM (IC50) | ChEMBL |
| CHEMBL142414 | ↓ inhibits | Mechanistic | 220.0 nM (IC50) | ChEMBL |
| CHEMBL142944 | ↓ inhibits | Mechanistic | 250.0 nM (IC50) | ChEMBL |
| CHEMBL25637 | ↓ inhibits | Mechanistic | 110.0 nM (IC50) | ChEMBL |
| CHEMBL356726 | ↓ inhibits | Mechanistic | 9200.0 nM (Ki) | ChEMBL |
| CHEMBL356089 | ↓ inhibits | Mechanistic | 150.0 nM (IC50) | ChEMBL |
| CHEMBL422833 | ↓ inhibits | Mechanistic | 240.0 nM (IC50) | ChEMBL |
| CHEMBL146839 | ↓ inhibits | Mechanistic | 20000.0 nM (Ki) | ChEMBL |
| CHEMBL140514 | ↓ inhibits | Mechanistic | 400.0 nM (IC50) | ChEMBL |
| CHEMBL140268 | ↓ inhibits | Mechanistic | 700.0 nM (IC50) | ChEMBL |
| CHEMBL436011 | ↓ inhibits | Mechanistic | 9000.0 nM (IC50) | ChEMBL |
| CHEMBL140317 | ↓ inhibits | Mechanistic | 9500.0 nM (IC50) | ChEMBL |
| CHEMBL140586 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL358546 | ↓ inhibits | Mechanistic | 55000.0 nM (Ki) | ChEMBL |
| CHEMBL140636 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL148905 | ↓ inhibits | Mechanistic | 73000.0 nM (Ki) | ChEMBL |
| CHEMBL344911 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
Showing top 40 of 184 agents ranked by evidence tier.
GLP1R
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHEMBL:CHEMBL607309 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL585444 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1327172 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1224483 | ? unclear | Mechanistic | DGIdb | |
| CGP13501 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580340 | ? unclear | Mechanistic | DGIdb | |
| EFPEGLENATIDE | ↑ activates | Mechanistic | DGIdb | |
| LIRAGLUTIDE | ? unclear | Mechanistic | DGIdb | |
| DULOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL597251 | ? unclear | Mechanistic | DGIdb | |
| ANGUSTIBALIN | ? unclear | Mechanistic | DGIdb | |
| DULAGLUTIDE | ↑ activates | Mechanistic | DGIdb | |
| EXENATIDE | ↑ activates | Mechanistic | DGIdb | |
| MOFEBUTAZONE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL532412 | ? unclear | Mechanistic | DGIdb | |
| NORTRIPTYLINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL533602 | ? unclear | Mechanistic | DGIdb | |
| PEGSEBRENATIDE | ↑ activates | Mechanistic | DGIdb | |
| OLANZAPINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL317115 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1549738 | ? unclear | Mechanistic | DGIdb | |
| CYCLOASPEPTIDE A | ? unclear | Mechanistic | DGIdb | |
| SCOULERINE | ? unclear | Mechanistic | DGIdb | |
| KEPONE | ? unclear | Mechanistic | DGIdb | |
| PEGAPAMODUTIDE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL603154 | ? unclear | Mechanistic | DGIdb | |
| ETOPOSIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL405914 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1308346 | ? unclear | Mechanistic | DGIdb | |
| FIDUXOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CLOZAPINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL578515 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1439833 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL601351 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580727 | ? unclear | Mechanistic | DGIdb | |
| AMORFRUTIN A | ? unclear | Mechanistic | DGIdb | |
| PROPIONYLPROMAZINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL588038 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1420370 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580207 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 166 agents ranked by evidence tier.
INSR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TESOFENSINE | ? unclear | Mechanistic | DGIdb | |
| INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN | ↑ activates | Mechanistic | DGIdb | |
| GO-6976 | ? unclear | Mechanistic | DGIdb | |
| INSULIN ZINC, PROMPT | ↑ activates | Mechanistic | DGIdb | |
| INSULIN PURIFIED PORK | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC SUSP EXTENDED PURIFIED BEEF | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC, EXTENDED | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC SUSP EXTENDED BEEF | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC SUSP BEEF | ↑ activates | Mechanistic | DGIdb | |
| INSULIN SENSITIZER S-707106 | ? unclear | Mechanistic | DGIdb | |
| SP-600125 | ? unclear | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| INSULIN DETEMIR | ↑ activates | Mechanistic | DGIdb | |
| INSULIN DEGLUDEC | ↑ activates | Mechanistic | DGIdb | |
| AEW-541 | ? unclear | Mechanistic | DGIdb | |
| ILORASERTIB | ? unclear | Mechanistic | DGIdb | |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| INSULIN ASPART PROTAMINE RECOMBINANT | ↑ activates | Mechanistic | DGIdb | |
| INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF | ↑ activates | Mechanistic | DGIdb | |
| INSULIN, PROTAMINE ZINC | ↑ activates | Mechanistic | DGIdb | |
| INSULIN TREGOPIL | ↑ activates | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ↑ activates | Mechanistic | DGIdb | |
| PF-562271 | ? unclear | Mechanistic | DGIdb | |
| INSULIN SUSP PROTAMINE ZINC PURIFIED PORK | ↑ activates | Mechanistic | DGIdb | |
| RECOMBINANT HUMAN KALLIKREIN-1 | ? unclear | Mechanistic | DGIdb | |
| LINIFANIB | ? unclear | Mechanistic | DGIdb | |
| INSULIN [INJECTION], BIPHASIC | ↑ activates | Mechanistic | DGIdb | |
| INSULIN HUMAN, ISOPHANE | ↑ activates | Mechanistic | DGIdb | |
| INSULIN SUSP ISOPHANE PURIFIED PORK | ↑ activates | Mechanistic | DGIdb | |
| INSULIN ZINC SUSP PURIFIED PORK | ↑ activates | Mechanistic | DGIdb | |
| RG-1530 | ? unclear | Mechanistic | DGIdb | |
| EPIRUBICIN | ? unclear | Mechanistic | DGIdb | |
| INSULIN ASPART PROTAMINE, HUMAN | ↑ activates | Mechanistic | DGIdb | |
| TOZASERTIB | ? unclear | Mechanistic | DGIdb | |
| TOPIRAMATE | ? unclear | Mechanistic | DGIdb | |
| LINSITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| INSULIN LISPRO | ↑ activates | Mechanistic | DGIdb | |
| INSULIN LISPRO PROTAMINE RECOMBINANT | ↑ activates | Mechanistic | DGIdb | |
| INSULIN SUSP ISOPHANE BEEF/PORK | ↑ activates | Mechanistic | DGIdb | |
| MITOGLITAZONE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 78 agents ranked by evidence tier.
IRS1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AGANIRSEN | ? unclear | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| FLUOROURACIL | ? unclear | Mechanistic | DGIdb | |
| DEHYDRATED ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| PRASTERONE | ? unclear | Mechanistic | DGIdb | |
| EPIRUBICIN | ? unclear | Mechanistic | DGIdb | |
| INOSITOL | ? unclear | Mechanistic | DGIdb | |
| GLIMEPIRIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL1685056 | ↓ inhibits | Mechanistic | 50.0 nM (Kd) | ChEMBL |
| CHEMBL1685055 | ↓ inhibits | Mechanistic | 150.0 nM (Kd) | ChEMBL |
| CHEMBL1681823 | ↓ inhibits | Mechanistic | 50.0 nM (Kd) | ChEMBL |
| CHEMBL4536878 | ↓ inhibits | Mechanistic | 120.0 nM (Kd) | ChEMBL |
| CHEMBL4591779 | ↓ inhibits | Mechanistic | 16200.0 nM (Kd) | ChEMBL |
| CHEMBL4530453 | ↓ inhibits | Mechanistic | 1600.0 nM (Kd) | ChEMBL |
| CHEMBL1572640 | ↓ inhibits | Mechanistic | 3300.0 nM (Kd) | ChEMBL |
| CHEMBL4576057 | ↓ inhibits | Mechanistic | 16400.0 nM (Kd) | ChEMBL |
LEPR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| MIBAVADEMAB | ↑ activates | Mechanistic | DGIdb | |
| SIMVASTATIN | ? unclear | Mechanistic | DGIdb | |
| VALPROIC ACID | ? unclear | Mechanistic | DGIdb | |
| METRELEPTIN | ↑ activates | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| SETMELANOTIDE | ? unclear | Mechanistic | DGIdb |
PPARG
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METHOXYCHLOR | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2208197 | ? unclear | Mechanistic | DGIdb | |
| PROPYLPYRAZOLETRIOL | ? unclear | Mechanistic | DGIdb | |
| LANIFIBRANOR | ↑ activates | Mechanistic | DGIdb | |
| PROPYLPARABEN | ? unclear | Mechanistic | DGIdb | |
| ABIETIC ACID | ? unclear | Mechanistic | DGIdb | |
| KEPONE | ? unclear | Mechanistic | DGIdb | |
| SPIRONOLACTONE | ? unclear | Mechanistic | DGIdb | |
| FLUOXASTROBIN | ? unclear | Mechanistic | DGIdb | |
| ROSIGLITAZONE MALEATE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2178583 | ? unclear | Mechanistic | DGIdb | |
| NAVEGLITAZAR | ↑ activates | Mechanistic | DGIdb | |
| CELECOXIB | ? unclear | Mechanistic | DGIdb | |
| SHINPTEROCARPIN | ? unclear | Mechanistic | DGIdb | |
| PSAMMAPLIN A | ? unclear | Mechanistic | DGIdb | |
| TECNAZENE | ? unclear | Mechanistic | DGIdb | |
| MYCOPHENOLATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1833984 | ? unclear | Mechanistic | DGIdb | |
| IMIGLITAZAR | ↑ activates | Mechanistic | DGIdb | |
| ROSIGLITAZONE | ? unclear | Mechanistic | DGIdb | |
| CLX-0921 | ↑ activates | Mechanistic | DGIdb | |
| AVE0847 | ↑ activates | Mechanistic | DGIdb | |
| CHLORFENAPYR | ? unclear | Mechanistic | DGIdb | |
| PIOGLITAZONE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| PROCHLORAZ | ? unclear | Mechanistic | DGIdb | |
| MESALAMINE | ↑ activates | Mechanistic | DGIdb | |
| BEZAFIBRATE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL312032 | ? unclear | Mechanistic | DGIdb | |
| ISOSILYBIN A | ? unclear | Mechanistic | DGIdb | |
| AMORFRUTIN A | ? unclear | Mechanistic | DGIdb | |
| NALED | ? unclear | Mechanistic | DGIdb | |
| TROGLITAZONE | ↑ activates | Mechanistic | DGIdb | |
| PROSTAGLANDIN D2 | ? unclear | Mechanistic | DGIdb | |
| INT131 | ~ modulates | Mechanistic | DGIdb | |
| EFATUTAZONE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| FLUORODIFEN | ? unclear | Mechanistic | DGIdb | |
| FLUDIOXONIL | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL166112 | ? unclear | Mechanistic | DGIdb | |
| BENSULIDE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 127 agents ranked by evidence tier.
PRKAA1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| GW441756X | ? unclear | Mechanistic | DGIdb | |
| PD-0166285 | ? unclear | Mechanistic | 316.23 nM (Ki) | DGIdb |
| CENISERTIB | ? unclear | Mechanistic | DGIdb | |
| CYC-116 | ? unclear | Mechanistic | 501.19 nM (Ki) | DGIdb |
| PENTOSTATIN | ? unclear | Mechanistic | DGIdb | |
| PALBOCICLIB | ? unclear | Mechanistic | DGIdb | |
| JNJ-7706621 | ? unclear | Mechanistic | 1700.0 nM (Kd) | DGIdb |
| PF-562271 | ? unclear | Mechanistic | DGIdb | |
| TOZASERTIB | ? unclear | Mechanistic | 1100.0 nM (Kd) | DGIdb |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| DOVITINIB | ? unclear | Mechanistic | 520.0 nM (Kd) | DGIdb |
| TYROSINE KINASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| METFORMIN | ? unclear | Mechanistic | DGIdb | |
| RG-1530 | ? unclear | Mechanistic | DGIdb | |
| LY-2090314 | ? unclear | Mechanistic | 630.96 nM (Ki) | DGIdb |
| ADENOSINE DEAMINASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| SAPONARIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL587615 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1997335 | ? unclear | Mechanistic | DGIdb | |
| ENTRECTINIB | ? unclear | Mechanistic | 251.19 nM (Ki) | DGIdb |
| SIROLIMUS | ? unclear | Mechanistic | DGIdb | |
| ILORASERTIB | ? unclear | Mechanistic | DGIdb | |
| TETRADECANOYLPHORBOL ACETATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL379975 | ? unclear | Mechanistic | DGIdb | |
| HESPERADIN | ↓ inhibits | Mechanistic | 19.0 nM (Kd) | DGIdb |
| PHENFORMIN | ? unclear | Mechanistic | DGIdb | |
| THYROXINE | ? unclear | Mechanistic | DGIdb | |
| ACADESINE | ↑ activates | Mechanistic | DGIdb | |
| CHEMOPREVENTIVE AGENT | ? unclear | Mechanistic | DGIdb | |
| SOTRASTAURIN | ? unclear | Mechanistic | 630.96 nM (Ki) | DGIdb |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| METFORMIN HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| SUNITINIB | ↓ inhibits | Mechanistic | 52.0 nM (Kd) | ChEMBL |
| ALVOCIDIB | ↓ inhibits | Mechanistic | 6600.0 nM (Kd) | ChEMBL |
| STAUROSPORINE | ↓ inhibits | Mechanistic | 9.0 nM (Kd) | ChEMBL |
| VANDETANIB | ↓ inhibits | Mechanistic | 10000.0 nM (Kd) | ChEMBL |
| AST-487 | ↓ inhibits | Mechanistic | 1400.0 nM (Kd) | ChEMBL |
| RAF-265 | ↓ inhibits | Mechanistic | 4500.0 nM (Kd) | ChEMBL |
| MIDOSTAURIN | ↓ inhibits | Mechanistic | 180.0 nM (Kd) | ChEMBL |
| SU-014813 | ↓ inhibits | Mechanistic | 100.0 nM (Kd) | ChEMBL |
Showing top 40 of 202 agents ranked by evidence tier.
SLC2A4
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PROTEASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| CLOFIBRATE | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL 3-BENZOATE | ? unclear | Mechanistic | DGIdb | |
| GLUFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| CALCIUM CHANNEL BLOCKER | ? unclear | Mechanistic | DGIdb | |
| BUTHIONINE SULFOXIMINE | ? unclear | Mechanistic | DGIdb | |
| THEAFLAVIN | ? unclear | Mechanistic | DGIdb | |
| TROGLITAZONE | ? unclear | Mechanistic | DGIdb | |
| TCDD | ? unclear | Mechanistic | DGIdb | |
| STAUROSPORINE | ? unclear | Mechanistic | DGIdb | |
| GENISTEIN | ? unclear | Mechanistic | DGIdb | |
| HEPARIN | ? unclear | Mechanistic | DGIdb | |
| GLYBURIDE | ? unclear | Mechanistic | DGIdb | |
| EPINEPHRINE | ? unclear | Mechanistic | DGIdb | |
| SOMATROPIN (RECOMBINANT DNA ORIGIN) | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| PRASTERONE | ? unclear | Mechanistic | DGIdb | |
| PD-98059 | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| NYSTATIN | ? unclear | Mechanistic | DGIdb | |
| RESVERATROL | ? unclear | Mechanistic | DGIdb | |
| LIOTHYRONINE | ? unclear | Mechanistic | DGIdb | |
| SORBITOL | ? unclear | Mechanistic | DGIdb | |
| IMATINIB | ? unclear | Mechanistic | DGIdb | |
| SOYBEAN SEED OIL | ? unclear | Mechanistic | DGIdb | |
| FLUORODEOXYGLUCOSE F18 | ? unclear | Mechanistic | DGIdb | |
| WORTMANNIN | ? unclear | Mechanistic | DGIdb | |
| RETINOIC ACID AGENT | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| BETA-ADRENERGIC ANTAGONIST | ? unclear | Mechanistic | DGIdb | |
| INDINAVIR | ? unclear | Mechanistic | DGIdb | |
| OMAPATRILAT | ? unclear | Mechanistic | DGIdb | |
| DEXAMETHASONE | ? unclear | Mechanistic | DGIdb | |
| UCN-01 | ? unclear | Mechanistic | DGIdb | |
| HALOPERIDOL DECANOATE | ? unclear | Mechanistic | DGIdb | |
| GREEN TEA LEAF EXTRACT | ? unclear | Mechanistic | DGIdb | |
| IRBESARTAN | ? unclear | Mechanistic | DGIdb | |
| TNF-ALPHA | ? unclear | Mechanistic | DGIdb | |
| ADENOVIRUS VECTOR | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 65 agents ranked by evidence tier.
SLC5A2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TOFOGLIFLOZIN | ↓ inhibits | Mechanistic | DGIdb | |
| SERGLIFLOZIN ETABONATE | ↓ inhibits | Mechanistic | DGIdb | |
| IPRAGLIFLOZIN | ↓ inhibits | Mechanistic | DGIdb | |
| LICOGLIFLOZIN | ↓ inhibits | Mechanistic | DGIdb | |
| HENAGLIFLOZIN | ↓ inhibits | Mechanistic | DGIdb | |
| YM-543 | ↓ inhibits | Mechanistic | DGIdb | |
| GLUFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| DAPAGLIFLOZIN PROPANEDIOL | ↓ inhibits | Mechanistic | DGIdb | |
| IPRAGLIFLOZIN L-PROLINE | ↓ inhibits | Mechanistic | DGIdb | |
| REMOGLIFLOZIN ETABONATE | ↓ inhibits | Mechanistic | DGIdb | |
| ERTUGLIFLOZIN PIDOLATE | ↓ inhibits | Mechanistic | DGIdb | |
| EMPAGLIFLOZIN | ↓ inhibits | Mechanistic | DGIdb | |
| ERTUGLIFLOZIN | ↓ inhibits | Mechanistic | DGIdb | |
| SOTAGLIFLOZIN | ↓ inhibits | Mechanistic | DGIdb | |
| CANAGLIFLOZIN | ↓ inhibits | Mechanistic | DGIdb | |
| BEXAGLIFLOZIN | ↓ inhibits | Mechanistic | DGIdb | |
| TOFOGLIFLOZIN ANHYDROUS | ? unclear | Mechanistic | Open Targets | |
| DAPAGLIFLOZIN | ? unclear | Mechanistic | 1.1 nM (EC50) | Open Targets |
| CHEMBL183937 | ↓ inhibits | Mechanistic | 4.0 nM (Ki) | ChEMBL |
| CHEMBL187805 | ↓ inhibits | Mechanistic | 10.0 nM (Ki) | ChEMBL |
| CHEMBL187163 | ↓ inhibits | Mechanistic | 9.0 nM (Ki) | ChEMBL |
| CHEMBL187749 | ↓ inhibits | Mechanistic | 10.0 nM (Ki) | ChEMBL |
| CHEMBL184530 | ↓ inhibits | Mechanistic | 230.0 nM (Ki) | ChEMBL |
| CHEMBL184027 | ↓ inhibits | Mechanistic | 70.0 nM (Ki) | ChEMBL |
| CHEMBL188013 | ↓ inhibits | Mechanistic | 40.0 nM (Ki) | ChEMBL |
| CHEMBL361672 | ↓ inhibits | Mechanistic | 520.0 nM (Ki) | ChEMBL |
| CHEMBL187056 | ↓ inhibits | Mechanistic | 290.0 nM (Ki) | ChEMBL |
| CHEMBL360824 | ↓ inhibits | Mechanistic | 1280.0 nM (Ki) | ChEMBL |
| CHEMBL184364 | ↓ inhibits | Mechanistic | 10.0 nM (Ki) | ChEMBL |
| CHEMBL359962 | ↓ inhibits | Mechanistic | 10.0 nM (Ki) | ChEMBL |
| CHEMBL184183 | ↓ inhibits | Mechanistic | 30.0 nM (Ki) | ChEMBL |
| CHEMBL183790 | ↓ inhibits | Mechanistic | 150.0 nM (Ki) | ChEMBL |
| CHEMBL365222 | ↓ inhibits | Mechanistic | 20.0 nM (Ki) | ChEMBL |
| CHEMBL187686 | ↓ inhibits | Mechanistic | 110.0 nM (Ki) | ChEMBL |
| CHEMBL186823 | ↓ inhibits | Mechanistic | 30.0 nM (Ki) | ChEMBL |
| CHEMBL187060 | ↓ inhibits | Mechanistic | 20.0 nM (Ki) | ChEMBL |
| CHEMBL362365 | ↓ inhibits | Mechanistic | 80.0 nM (Ki) | ChEMBL |
| CHEMBL183689 | ↓ inhibits | Mechanistic | 70.0 nM (Ki) | ChEMBL |
| CHEMBL371448 | ↓ inhibits | Mechanistic | 491.0 nM (IC50) | ChEMBL |
| CHEMBL382302 | ↓ inhibits | Mechanistic | 458.0 nM (IC50) | ChEMBL |
Showing top 40 of 190 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Searched directly from “Type 2 Diabetes” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 12-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
60 agents shown (approved or with trial evidence) — 45 not found by the gene-target search above.
Dapagliflozin
Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00839683 NCT01042977 NCT03074630
Glimepiride
Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00747383 NCT02769481 NCT00099944
metformin
Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT01941199 NCT02119819 NCT06120881
simvastatin
Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00839683 NCT00839683
vildagliptin
Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00237237 NCT00099944
Technosphere® Insulin Inhalation PowderNOT in gene-target list
· 2 trials · source: ClinicalTrials.gov
NCT00662857 NCT00662857
Semaglutide
Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT07564414 NCT00833716
valsartanNOT in gene-target list
Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00839683
Sitagliptin
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00747383
RosuvastatinNOT in gene-target list
Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03074630
Liraglutide injection,RD12014NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05294536
Liraglutide injection,VictozaNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05294536
Salba dietNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT00362011
Tang-min-ling pills low dosageNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01107171
Tang-min-ling pills high dosageNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01107171
GSBR-1290NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05762471
HydrochlorothiazideNOT in gene-target list
Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00976495
Finerenone (Kerendia, BAY 948862)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05526157
Sodium-glucose cotransporter 2 inhibitors (SGLT2i)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05526157
Glucagon-like peptide-1 receptor agonists (GLP 1 RA)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05526157
Steroidal mineral corticoid receptor antagonists (sMRA)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05526157
Non-steroidal mineral corticoid receptor antagonists (nsMRA)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05526157
Bexagliflozin
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02769481
Placebo for BexagliflozinNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02769481
Placebo for GlimepirideNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02769481
PRECEDE HPE modelNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01316367
CHPENOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01316367
Bromocriptine-QRNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05405244
FinerenoneNOT in gene-target list
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06727409
DA-1229NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01941199
DA-1229 + metforminNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01941199
Clenbuterol HydrochlorideNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT04921306
Non-ARB (standard therapy)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01075698
ARB (Telmisartan)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01075698
blood donationNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT00230087
Pioglitazone
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00331487
Rosiglitazone
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00331487
RAA PopulationNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT00662857
Metformin glycinate
Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01386671
Metformin hydrochloride
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01386671
Potato-based side dishNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03495284
Refined grain-basedNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03495284
LY3841136NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06603571
Tirzepatide
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06603571
LAF237 placeboNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT00099944
CagrisemaNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT07564414
LY2944876NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02119819
Exenatide extended-releaseNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02119819
aleglitazar
Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01871428
Black Impact InterventionNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06055036
Insulin glargine,300 U/mLNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02735044
Insulin glargine (100 units /mL)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02735044
Background therapyNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT02735044
Enhanced GI Concept EducationNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT03037099
Video-Based Diabetes Self-Management Education and Support (DSMES)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06319716
Community Health Worker (CHW) SupportNOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06319716
Kerendia (Finerenone, BAY94-8862)NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT06906081
LY2189265NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT01558271
Liraglutide
Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01558271
AP-325NOT in gene-target list
· 1 trial · source: ClinicalTrials.gov
NCT05160272